OlympHill
PathAI logo

PathAIAI驱动病理学平台的精准诊断和生物标志物发现平台。

4.3 (6)
Daniel Nikulshyn审阅者 Daniel Nikulshyn·更新 2026年7月

概览

我们公司的使命是通过可靠的 AI 驱动技术和有意义的合作来改善患者疗效。我们通过为生物标志物发现和药物研发提供宝贵见解,并改进实验室工作流程来实现这一目标。 在 PathAI,我们提供一个基于 AI 的病理学平台,用于精准诊断和生物标志物发现。该平台包括一个云原生、开放平台的企业工作流程解决方案 AISight,作为案例管理、图像管理以及行业顶尖人工智能工具的核心枢纽。此解决方案支持多种组织病理学用例,例如案例管理、图像管理和 AI 应用。 我们拥有一个专有的病理学家贡献者网络,成员超过450名持牌病理学家,累计贡献了3250万条标注,协助训练和验证我们的 AI 算法。我们的技术被领先的实验室和研究中心用于推动其数字病理工作流和 AI 应用。 我们公司已与多家机构合作,包括 MedStar Health 和 Labcorp,部署我们的数字病理平台和先进的 AI 应用。我们还获得了 FDA 对 AISight Dx 平台用于初级诊断的批准。 PathAI 是一家领先的 AI 驱动病理学公司,我们致力于通过人工智能的力量推进精准医学。我们的团队热衷于解决医疗健康领域的大难题,并用人工智能改变病理学领域。

主要功能

  • 通过AI辅助组织和幻灯片分析
  • 生物标志物检测和定量
  • 临床试验和转化研究工具
  • 数字病理学实验室集成
  • 配套诊断开发支持
  • 病理学家合作工具

价格

模型
Freemium
评分
4.3 / 5 (6)

使用场景

加速肿瘤生物标志物发现

生物制药研究人员使用PathAI在大规模组织样本数据集中检测和定量生物标志物,促进肿瘤计划的转化医学和靶向识别。

丰富临床试验队列

制药团队利用AI辅助幻灯片分析来识别合格患者并根据组织级特征划分队列,改善试验丰富性和结果。

支持 Routine 临床诊断

医院病理学实验室将PathAI集成到数字工作流程中,以辅助病理学家根据一致性更强和准确性更高的案例进行生物活检分析。

开发配套诊断

诊断开发者与PathAI合作,建造和验证AI驱动的配套诊断来伴随靶向治疗实现精准医学应用。

优点 & 缺点

优点

  • 注重临床级准确度
  • 被大型制药和研究机构使用
  • 支持生物标志物定量化
  • 与数字病理学工作流程集成

缺点

  • 针对企业和实验室用户,不针对个人
  • 需要数字幻灯片基础设施
  • 有限的公共定价透明度

评测

4.3

6 个评分的平均值。

5
2
4
4
3
0
2
0
1
0

登录以留下评测。

AK

Aisha Khan

May 15, 2026

Use it every day

Honestly didn't expect to like it this much. Biomarker detection and quantification is exactly what I needed, and strong focus on clinical-grade accuracy. I do wish requires digitized slide infrastructure, but I reach for it almost every day now and it just clicks.

Fatima Zahra

Fatima Zahra

Mar 26, 2026

Skeptical, then convinced

I went in skeptical — most tools in this space overpromise. It actually delivers on aI-assisted tissue and slide analysis, and strong focus on clinical-grade accuracy caught me off guard. still, I'd recommend giving it a real trial.

Mei-Ling Wong

Mei-Ling Wong

Dec 24, 2025

Does the job

Pretty happy overall. Biomarker detection and quantification just works and integrates with digital pathology workflows. but no dealbreakers — I'd recommend it to a friend without hesitating.

JK

Joanna Kowalski

Jul 17, 2025

Years in this space

I've evaluated a lot of these over the years. What stands out here is collaboration tools for pathologists — handled better than most — and integrates with digital pathology workflows. Targeted at enterprise and lab users, not individuals is my one real gripe. Worth the time if this is your use case.

Robert Ainsworth

Robert Ainsworth

Jun 27, 2025

Compared a few options

Evaluated this against two competitors. Where it wins: biomarker detection and quantification and strong focus on clinical-grade accuracy. Where it lags: requires digitized slide infrastructure. On balance the feature set — especially biomarker detection and quantification — justifies the 4 stars for our use case.

Frank Müller

Frank Müller

Jun 14, 2025

Compared a few options

Evaluated this against two competitors. Where it wins: companion diagnostic development support and supports biomarker quantification at scale. Where it lags: targeted at enterprise and lab users, not individuals. On balance the feature set — especially biomarker detection and quantification — justifies the 4 stars for our use case.

问答

Is PathAI suitable for individual users?

No, PathAI is primarily targeted at enterprise and lab users, not individuals.

Asked by Celeste Marchetti · Feb 26, 2026

What are the key features of PathAI's platform?

Key features include AI-assisted tissue and slide analysis, biomarker detection, and clinical trial tools, among others.

Asked by Ingrid Bauer · Feb 16, 2026

Can PathAI integrate with existing lab workflows?

Yes, PathAI's platform supports digital pathology lab integration and collaborates with existing workflows.

Asked by Mireille Dupont · Jan 11, 2026

What is PathAI's pricing model?

Pricing details are not publicly available, and the platform is targeted at enterprise and lab users.

Asked by Valentina Marino · Dec 4, 2025

提问

筑得制回丿题图 的替代品